How GLP-1 drugs, regulatory concerns, and more factors are shaping the sector. Plus, 3 undervalued healthcare stocks.

In the last year, some drugmakers have pulled back from the sector, including Pfizer, which recently stopped selling its gene ...

A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...

The diabetes market is booming, with continuous glucose monitoring (CGM) and GLP-1 drugs leading the charge in innovation and ...

Both stocks should deliver excellent returns to investors patient enough to hold through volatility. Equity markets started ...

Vertex Pharmaceuticals is ranked among the best biotech stocks to buy, with 13 billionaires backing the company. Despite ...

Financing extends Arbor’s cash runway into 2027 and supports the clinical development of lead program ABO-101 and continued advancement of a broader portfolio of CNS-targeted gene editing therapeutics ...

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ...

Latigo Biotherapeutics has whipped together a $150 million series B fundraising round to advance a pipeline of non-opioid ...

Pacira BioSciences, Inc.'s stock is up 33%, backed by a new Exparel patent, growth strategies, and market trends. Click here ...

Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” fourth quarter 2024 ...

The pipeline exceeded its original intended full-service start ... but no delay analysis had been done. Miltonberger now ...